SKYRIZI (risankizumab-rzaa) by AbbVie Inc.



Physician Resources
3 FILES

Physician Resources
Patient Resources
5 FILES

Patient Resources
Savings and Support
10 FILES

Savings & Support
Indications & Usage

INDICATIONS AND USAGE

 

SKYRIZI is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 

 

Please see full Prescribing Information.

Dosage & Administration

DOSAGE AND ADMINISTRATION

 

150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.

 

Please see full Prescribing Information.

Warnings & Precautions

WARNINGS AND PRECAUTIONS

 

  • Infections: SKYRIZI may increase the risk of infection. Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI.  Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops an infection, or is not responding to standard therapy, monitor the patient closely and do not administer SKYRIZI until the infection resolves.
  • Tuberculosis (TB): Evaluate for TB prior to initiating treatment with SKYRIZI. Consider anti-TB therapy prior to initiating SKYRIZI in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
  • Immunizations: Prior to initiating therapy with SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI. No data are available on the response to live or inactive vaccines.


Please see full Prescribing Information.

Adverse Reactions

ADVERSE REACTIONS

 

Most common adverse reactions (≥ 1%) are upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

 

To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

 

Please see full Prescribing Information.

Drug Interactions

DRUG INTERACTIONS

 

Avoid use of live vaccines in patients treated with SKYRIZI.

 

Please see full Prescribing Information.

US-SKZD-200194

©2020 AbbVie Inc. North Chicago, IL 60064.

Please see Full Prescribing Information.

Indication and Important Safety Information


INDICATION

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.